ArticleJournal of thoracic disease2013
The development of targeted therapy in small cell lung cancer.
Article in Journal of thoracic disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Prognostic significance of serum soluble DR5 levels in small-cell lung cancer.International journal of medical sciences · 2019Trial
- Aberrant N-glycosylation in cancer: MGAT5 and β1,6-GlcNAc branched N-glycans as critical regulators of tumor development and progression.Cellular oncology (Dordrecht, Netherlands) · 2023Review
- Prognostic value of NOX2 as a potential biomarker for lung adenocarcinoma using TCGA and clinical validation.Molecular medicine reports · 2023Article
- Efficacy of metformin adjunctive therapy as the treatment for non-diabetic patients with advanced non-small cell lung cancer: A Systematic review and Meta-analysis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Review
- Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies.Frontiers in pharmacology · 2021Review
- Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features.BioMed research international · 2021Article
- Prognostic significance of serum osteopontin levels in small cell lung cancer.BMC pulmonary medicine · 2020Article
- Using Dual Fluorescence Reporting Genes to Establish an In Vivo Imaging Model of Orthotopic Lung Adenocarcinoma in Mice.Molecular imaging and biology · 2016Article
- Apolipoproteins as Differentiating and Predictive Markers for Assessing Clinical Outcomes in Patients with Small Cell Lung Cancer.Yonsei medical journal · 2016Article
- Overexpression of MCPH1 inhibits uncontrolled cell growth by promoting cell apoptosis and arresting the cell cycle in S and G2/M phase in lung cancer cells.Oncology letters · 2016Article
- Phosphorylated 4E-binding protein 1 expression is associated with poor prognosis in small-cell lung cancer.Virchows Archiv : an international journal of pathology · 2015Article
- Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.BMC research notes · 2015Article
- Diabetes mellitus increases postoperative mortality in non-small cell lung cancer.Thoracic cancer · 2014Article
- ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer.PloS one · 2014Article
- An innocent appearing subcutaneous nodule diagnoses a small cell lung cancer in a never-smoker female.Case reports in oncological medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) is a highly aggressive cancer usually with distal metastasis and very poor prognosis. Chemotherapy is the treatment of choice for SCLC in all stages and an initial good response, but there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. Targeted drugs have less toxicity than chemotherapy drugs, but no targeted agents have been approved for use in the treatment of SCLC patients to date. This review focuses on targeted therapies in SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.